Farallon Capital Management LLC Purchases 2,275,000 Shares of Savara Inc (NASDAQ:SVRA)

Farallon Capital Management LLC grew its position in Savara Inc (NASDAQ:SVRA - Free Report) by 49.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,835,000 shares of the company's stock after purchasing an additional 2,275,000 shares during the period. Farallon Capital Management LLC owned about 3.98% of Savara worth $20,983,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cibc World Markets Corp bought a new stake in shares of Savara in the 4th quarter valued at about $33,000. XTX Topco Ltd acquired a new stake in Savara during the 4th quarter valued at $34,000. Ameriprise Financial Inc. acquired a new stake in Savara during the 4th quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara during the fourth quarter worth $41,000. Finally, Hsbc Holdings PLC bought a new position in shares of Savara in the fourth quarter worth $48,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Savara in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.83.

Savara Trading Down 11.2%

Shares of Savara stock traded down $0.36 during midday trading on Friday, reaching $2.86. The company had a trading volume of 1,964,507 shares, compared to its average volume of 1,301,730. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a fifty day moving average price of $2.90 and a 200 day moving average price of $3.04. The firm has a market cap of $494.06 million, a PE ratio of -6.65 and a beta of 0.44.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. On average, equities analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.